EUM: Noninvasive Monitoring of Uterine Electrical Activity and Fetal Heart Rate: A New External Monitoring Device

Sponsor
Montefiore Medical Center (Other)
Overall Status
Suspended
CT.gov ID
NCT02993354
Collaborator
(none)
55
1
50.7
1.1

Study Details

Study Description

Brief Summary

The EUM (electrical uterine myography) (OB Tools, Israel) was tested and found to be reliable as a non-invasive method for evaluating uterine contractions and the fetal heart rate. It is safe and effective in monitoring uterine contractions. The investigators propose to perform a series of studies to validate the accuracy and clinical usefulness of the EUM device by simultaneously monitoring patients with current methods (with either external or internal devices) as clinically indicated and with the EUM device. Providers will be blinded to the results of the EUM device. The investigators will continue care as per current guidelines using the information obtained from the current monitoring methods. Information obtained from the EUM devices will not be used to determine the clinical course of action.

Condition or Disease Intervention/Treatment Phase
  • Device: The EUM300 (electrical uterine myography)

Detailed Description

Purpose:

The investigators propose to perform a study to validate the accuracy and clinical usefulness of the EUM device by comparing it with simultaneous use of current methods (both external or internal devices) among obese patients and patients with normal body mass indexes (BMI).

Objectives:
  1. Compare the contractions obtained using the EUM device vs. those obtained using the intrauterine pressure catheter vs. those obtained from external tocodynamometer among current obese patients (BMI greater than 30 kg/m2) and nonobese patients using simultaneously obtained, 30 minute tracings with regards to the frequency of contractions, the duration of contractions, maximum height of the contractions, the total Montevideo units recorded, the timing of the contractions, and the amount of discontinuous tracings from the devices.

  2. Compare the fetal heart rate tracing obtained via the EUM device vs. external fetal Doppler vs. fetal scalp electrode (simultaneously obtained, 30 minute tracings will be compared) among obese patients and nonobese patients with regards to the amount of discontinuous/unterinterpetable tracing, average fetal heart rate, baseline heart rate, the number accelerations, the number of decelerations, the timing of the accelerations, the timing of decelerations, the maximum fetal heart rate achieved during acceleration, the lowest fetal heart rate achieved during deceleration, and compare the degree of variability in the tracing.

  3. Compare tracings of productive vs. non-productive contractions in patients presenting to triage to rule out labor (30 minutes of simultaneously obtained tracings of external tocodynamometer and EUM device will be compared) with regards to the frequency of contractions, the duration of contractions, maximum height of contractions, the timing of the contractions and the amount of discontinuous tracings from both devices, as well as changes in cervical exam on the basis of body mass index.

Study Design

Study Type:
Observational
Anticipated Enrollment :
55 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Noninvasive Monitoring of Uterine Electrical Activity and Fetal Heart Rate: A New External Monitoring Device
Actual Study Start Date :
Jul 1, 2017
Anticipated Primary Completion Date :
Sep 21, 2021
Anticipated Study Completion Date :
Sep 21, 2021

Arms and Interventions

Arm Intervention/Treatment
Pregnant women

Pregnant women with singleton pregnancy with gestational age greater than or equal to 24 weeks.

Device: The EUM300 (electrical uterine myography)
External monitor intended for the evaluation of electrical signals originating in the uterus, thus providing a tool for measuring uterine activity as well as fetal heart rate.

Outcome Measures

Primary Outcome Measures

  1. Contractions [30 mins]

    1. Compare the contractions obtained using the EUM device vs. those obtained using the intrauterine pressure catheter vs. those obtained from external tocodynamometer among current obese patients (BMI greater than 30 kg/m2) and nonobese patients using simultaneously obtained, 30 minute tracings with regards to the frequency of contractions, the duration of contractions, maximum height of the contractions, the total Montevideo units recorded, the timing of the contractions, and the amount of discontinuous tracings from the devices.

  2. Fetal heart rate [30 mins]

    2. Compare the fetal heart rate tracing obtained via the EUM device vs. external fetal Doppler vs. fetal scalp electrode (simultaneously obtained, 30 minute tracings will be compared) among obese patients and nonobese patients with regards to the amount of discontinuous/unterinterpetable tracing, average fetal heart rate, baseline heart rate, the number accelerations, the number of decelerations, the timing of the accelerations, the timing of decelerations, the maximum fetal heart rate achieved during acceleration, the lowest fetal heart rate achieved during deceleration, and compare the degree of variability in the tracing.

Secondary Outcome Measures

  1. Productive Contractions [30 mins]

    3. Compare tracings of productive vs. non-productive contractions in patients presenting to triage to rule out labor (30 minutes of simultaneously obtained tracings of external tocodynamometer and EUM device will be compared) with regards to the frequency of contractions, the duration of contractions, maximum height of contractions, the timing of the contractions and the amount of discontinuous tracings from both devices, as well as changes in cervical exam on the basis of body mass index.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  1. Maternal age >18 years old

  2. Singleton pregnancy

  3. Gestational age of 24 completed weeks or greater based on the estimated due date as calculated from last menstrual period or early ultrasound

  4. Category I (reassuring) fetal heart rate tracing at time of enrollment

Exclusion Criteria:
  1. Fetal anomaly or chromosome defect

  2. Allergy to silver

  3. Woman with implanted electronic device of any kind

  4. Irritated skin or open wound on the abdominal wall

Contacts and Locations

Locations

Site City State Country Postal Code
1 Jack D. Weiler Hospital of Montefiore Medical Center Bronx New York United States 10461

Sponsors and Collaborators

  • Montefiore Medical Center

Investigators

  • Principal Investigator: Peter Bernstein, MD, Montefiore Medical Center

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Montefiore Medical Center
ClinicalTrials.gov Identifier:
NCT02993354
Other Study ID Numbers:
  • 2015-4881
First Posted:
Dec 15, 2016
Last Update Posted:
May 21, 2021
Last Verified:
May 1, 2021
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 21, 2021